Apollo HealthCo demerger: Q4 FY27 listing timeline

What Apollo Hospitals is aiming to do

Apollo Hospitals Enterprise Limited (AHEL) has reiterated that its planned demerger of Apollo HealthCo, its omnichannel digital health and pharmacy business, remains on track. Management has guided that the process is expected to conclude by Q4 FY27, when the standalone entity could be listed. The restructuring is positioned as a key step in streamlining the group’s portfolio while continuing its broader FY27 growth trajectory. The company has also outlined a clear operating target for the business post-restructuring, with a revenue run rate goal of ₹25,000 crore by Q4 FY27. The updates were shared through management commentary and reporting that referenced regulatory progress and upcoming shareholder actions.

Demerger timeline: June 24 shareholder vote and Q4 FY27 end date

AHEL’s management has said shareholder approval is slated for June, with a specific meeting date of June 24, 2026 mentioned as the point for final approval. The National Company Law Tribunal (NCLT) has already directed that a shareholders’ meeting be held. Apollo’s Group CFO, Krishnan Akhileswaran, said that once shareholder approval is in place, the demerger plan is expected to be completed by Q4 FY27. Management also reiterated its expectation that the overall process will finish within that timeline. Separately, the group has previously communicated that the new entity would be listed within an 18 to 21 month window from the announcement of the plan.

How the restructuring is structured: AHTL, HealthCo, and Keimed

The transaction is a multi-step composite scheme. As described in company and regulator updates, the identified business undertaking of AHEL will be demerged into Apollo Healthtech Limited (AHTL). After that, Apollo Healthco Ltd (AHL) and Keimed Pvt Ltd are slated to merge and amalgamate into AHTL. The end state is a consolidated digital health and pharmacy platform under AHTL, followed by listing of AHTL equity shares on the stock exchanges. The new entity is described as housing Apollo 24/7, the offline pharmacy business of Apollo HealthCo, Keimed, and the telehealth services business.

Regulatory clearances: CCI approval in Sep 2025, more pending

One key milestone already achieved is clearance from the Competition Commission of India (CCI). CCI approved the proposed combination on 23 September 2025, covering the demerger into AHTL and the subsequent merger and amalgamation of AHL and Keimed into AHTL. The company has also stated it has stock exchange approval and is expecting a no-objection certificate from the Securities and Exchange Board of India (SEBI). Management commentary indicated that additional clearances could take another six to eight months. These approvals, along with shareholder and NCLT steps, are central to hitting the Q4 FY27 completion target.

Financial and operating targets: breakeven and ₹25,000 crore run rate

Apollo HealthCo is expected to reach cash breakeven by the current quarter, Q1 FY27, according to a top company executive cited in Business Standard. On the revenue side, Apollo has said Apollo HealthCo is expected to be around ₹20,000 crore on a consolidated basis in the current year. The company’s stated objective is to reach a run rate of ₹25,000 crore by Q4 FY27 with a 7 percent EBITDA margin. Management has also linked the completion of the restructuring to the listing of the new company, framing the listing as the endpoint of the reorganisation.

Funding and portfolio moves: Cradle multiple and ₹750 crore from fertility deal

Alongside the HealthCo restructuring, Apollo Hospitals has described steps to streamline its broader portfolio. The company has referenced merging its Cradle business at a 35X EBITDA multiple. It has also said it raised ₹750 crore from its fertility business merger. Apollo indicated these funds are earmarked for expansion in diagnostics and primary care. In the same context, the company has positioned the HealthCo consolidation and listing timeline for Q4 FY27 as a core part of the group’s medium-term plan.

International patient mix: Bangladesh impact eases, diversification helps

AHEL has also pointed to improved visibility in its overseas patient inflows after disruption linked to the Bangladesh crisis. The hospital chain said it is already out of the impact due to diversification into new regions. International patient revenue rose 28 percent year-on-year in Q3 FY26, according to the company. During the quarter, international patients were around 6 percent of total revenue, or ₹190 crore out of ₹3,183 crore in Q3 FY26. Company data also showed Bangladesh’s share of patient inflows dipped to 7 to 8 percent in Q3 FY26, from 30 percent in early 2024, while other regions including Africa, West Asia, and South East Asia increased.

Market impact: stock reaction and why investors focused on the listing

Apollo Hospitals Enterprise Ltd’s share price rose 4.73 percent on Tuesday after the group announced the listing plan for Apollo Healthtech Ltd, according to the cited market update. The price move highlighted investor focus on the value-unlock narrative tied to separating the pharmacy and digital health businesses. The structure also consolidates distribution and consumer-facing health platforms under one listed vehicle, which may improve transparency around unit economics as the business targets cash breakeven and a defined EBITDA margin. However, the company’s timeline still depends on completion of remaining regulatory processes and formal approvals already outlined.

Key facts at a glance

Conclusion: what to watch next

Apollo Hospitals has kept its messaging consistent: the HealthCo demerger is planned to conclude by Q4 FY27, with the June 24, 2026 shareholder meeting a key near-term checkpoint. The scheme consolidates Apollo’s pharmacy, digital health, telehealth, and distribution assets into Apollo Healthtech Ltd, which is intended to be listed after the demerger and mergers are completed. On operations, the company has guided for Apollo HealthCo to achieve cash breakeven in Q1 FY27 and reach a ₹25,000 crore revenue run rate by Q4 FY27 with a 7 percent EBITDA margin. The next set of milestones will depend on remaining regulatory steps, including the expected SEBI no-objection certificate and subsequent procedural approvals that management has said are in progress.